Protect high-value GLP-1 and cardiometabolic assets during complex portfolio transitions. Our validated platform ensures seamless integration without regulatory risk.
Book a technical walkthrough with our compliance team to secure your transition.
A successful cardiometabolic M&A cold chain strategy requires a unified digital layer that bridges disparate legacy systems. As portfolios expand to include sensitive metabolic therapies, maintaining product integrity through the merger is critical for patient safety and regulatory approval.
Consolidate multiple monitoring vendors into a single, validated dashboard to ensure cross-portfolio transparency and standard operating procedures.
Prevent temperature excursions in cardiometabolic products during facility transfers and shipping lane re-routing common in M&A activity.
Maintain a continuous audit trail through the acquisition phase, providing regulators with uninterrupted proof of product stability.
Evaluate the target company's current cold chain infrastructure and data integrity to identify compliance gaps before final integration.
Deploy TrueCold sensors across the new asset pool to establish a unified monitoring layer without replacing existing physical infrastructure.
Automatically synchronize all temperature data into your enterprise Quality Management System for a seamless, unified compliance record.
Integrating a new cardiometabolic division requires global visibility from day one. TrueCold provides the real-time insights needed to manage expanded logistics networks across multiple continents.
Our platform handles the massive data volumes generated by modern M&A, turning raw temperature logs into actionable business intelligence.
Our hardware-agnostic software can be deployed across acquired fleets in days, not months, ensuring no data loss during transition.
Predictive analytics identify potential lane failures before they occur, protecting high-value cardiometabolic inventory from spoilage.
Fully 21 CFR Part 11 compliant platform designed specifically for the rigorous requirements of pharmaceutical quality assurance.
Our platform is designed to ingest data from multiple sources through a unified API. We normalize disparate data formats into a single, validated stream, allowing you to maintain a consistent cardiometabolic M&A cold chain strategy regardless of the underlying hardware used by the acquired entity.
Yes, TrueCold is fully GxP validated. We provide a comprehensive validation package that supports 21 CFR Part 11 compliance, specifically tailored for the high-sensitivity requirements of modern metabolic and cardiometabolic therapeutics.
Initial data visibility can often be achieved within 72 hours of system access. A full enterprise-wide rollout, including hardware retrofitting if necessary and staff training, typically takes between 4 to 8 weeks depending on the scale of the acquisition.
Don't let operational fragmentation put your billion-dollar assets at risk. Implement a unified, validated monitoring strategy that grows with your company.